Quoin pharmaceuticals provides corporate update and announces second quarter 2024 financial results

Quoin broadens product portfolio through research agreement with university college cork, ireland company expands on-going clinical trials in netherton syndrome to include international sites announced plans to initiate clinical study in peeling skin syndrome continues to evaluate m&a opportunities in rare and orphan diseases ashburn, va., aug. 08, 2024 (globe newswire) -- quoin pharmaceuticals ltd.
QNRX Ratings Summary
QNRX Quant Ranking